Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. Journal of Carcinogenesis, [S. l.], v. 4, n. 1, 2005. Disponível em: https://carcinogenesis.com/index.php/JOC/article/view/262. Acesso em: 17 mar. 2026.